Arrowhead Pharmaceuticals finally knows the future of its hepatitis B med: Johnson & Johnson has offloaded the rights to GSK.Earlier this year, J&J’s Janssen unit began shrinking its infectious disease and vaccine portfolio, leaving several partners, including Arrowhead, unclear on the future of their partnerships. Arrowhead had been working with Janssen since 2018 on the […]
